480 related articles for article (PubMed ID: 25435542)
21. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
22. Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
Hallsson LR; Sroczynski G; Engel J; Siebert U
BMC Cancer; 2023 Jun; 23(1):590. PubMed ID: 37365514
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
24. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
27. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
30. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
32. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
[TBL] [Abstract][Full Text] [Related]
35. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract][Full Text] [Related]
36. Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
Lim KK; Yoon SY; Mohd Taib NA; Shabaruddin FH; Dahlui M; Woo YL; Thong MK; Teo SH; Chaiyakunapruk N
Appl Health Econ Health Policy; 2018 Jun; 16(3):395-406. PubMed ID: 29572724
[TBL] [Abstract][Full Text] [Related]
37. Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
Bommer C; Lupatsch J; Bürki N; Schwenkglenks M
Eur J Health Econ; 2022 Jul; 23(5):807-821. PubMed ID: 34767113
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of testing for breast cancer susceptibility genes.
Holland ML; Huston A; Noyes K
Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
[TBL] [Abstract][Full Text] [Related]
39. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
40. A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of
Best AF; Tucker MA; Frone MN; Greene MH; Peters JA; Katki HA
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):293-302. PubMed ID: 30692095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
